Agilent Technologies registers cedar creek facility with FDA to manufacture diagnostic products
SANTA CLARA Calif. -- Agilent Technologies Inc. (NYSE: A) today announced that its Cedar Creek, Texas, reagent manufacturing facility has been registered with the U.S. Food and Drug Administration as a medical device establishment. This registration is required for the manufacture of diagnostic products, which Agilent intends to develop.
'Many of Agilent's proven research platforms hold potential in diagnostic markets,' said Robert Schueren, Agilent vice president, Genomics. 'We've made a commitment to bring improved diagnostic tools to the medical community. Having an FDA-registered manufacturing facility is yet another step in this endeavor.'
Agilent currently manufactures and packages a wide range of research bioreagents at the 80,000-square-foot Cedar Creek facility, including enzyme-based reagents and high-fidelity oligonucleotides. The company has built separate, dedicated diagnostics space with additional room for expansion as needed.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications. The company's 18,500 employees serve customers in more than 100 countries. Agilent had net revenues of $5.4 billion in fiscal 2010. Information about Agilent is available at www.agilent.com.